Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Makarova (Chelyabinsk, Russian Federation), G. Ignatova (Chelyabinsk, Russian Federation). Assessment of biological therapy in asthma-obesity phenotype. 1408

Member's Comments

No comment yet.

Related content which might interest you: Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score. Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Fitness for radical treatment modalities: efficient functional assessment, improving fitness and fitness-adapted therapy concepts including the elderly Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 Clinical and pathophysiological features of asthma phenotypes Source: Annual Congress 2013 –Asthma at the bedside Year: 2013 The utility of HLA-DQB302 as a genetic marker to predict the effect of aspirin desensitization on lung function of patients with aspirin exacerbated respiratory disease Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Proof of concept study to evaluate step down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Menopausal asthma: a new biological phenotype? Source: Annual Congress 2009 - One size (does not) fit all: phenotyping and controlling asthma Year: 2009 Identification of molecular pathways in distinct asthma phenotypes identified in ADEPT Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Physical activity pattern of severe asthmatic patients treated with biological therapy. Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Individual dynamic of inflammatory markers as indicators of COPD treatment effectiveness Source: International Congress 2014 – COPD: points to ponder Year: 2014 Monitoring the inflammatory heterogeneity in asthma with multiple biomarkers for multidimensional endotyping Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Novel biomarker more strongly associated with tuberculosis treatment outcome than conventional or genotypic methods Source: International Congress 2015 – Science and biomarkers in TB Year: 2015 Interference RNA as a new tool and possible future therapy for inflammatory lung disease Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes Year: 2005 Functional independence measure scale in patients with lung cancer after chemotherapy Source: Annual Congress 2008 - Functionality and metabolism in rehabilitation candidates Year: 2008 Lung hypertension: developmental mechanisms and assesment therapeutic action efficiency Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 Assessment of thyroid function tests in COPD phenotypes Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 Is the association between physical activity and lung function due to reverse causation? An application of exploratory and causal approaches Source: International Congress 2019 – Tuberculosis epidemiology, bronchiectasis, other infections and spirometry Year: 2019